Physician profile
John Telegadis
NPI 1184666554
$17,962.03
in general payments reported to CMS, 2019-2025
47 companies · $2,905 in 2025
The $2,905 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,860 · 2020: $2,740 · 2021: $2,974 · 2022: $1,928 · 2023: $2,720 · 2024: $2,835 · 2025: $2,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,435 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16.07 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,434.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16.07 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,432.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,087.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,681.66 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,531.92 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $1,418.66 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,366.70 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,282.56 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $859.64 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $503.52 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $422.36 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Allergan, INC. | $410.93 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $393.06 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Exact Sciences Corporation | $330.37 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $322.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $302.77 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $252.35 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Electromed, INC. | $226.66 | 2021-2024 | Smartvest |
| Idorsia Pharmaceuticals US INC | $224.81 | 2023-2024 | Quviviq |
| Amgen INC. | $174.11 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $160.01 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $142.65 | 2019-2024 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $135.55 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $120.17 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $111.41 | 2022 | |
| Phathom Pharmaceuticals, INC. | $103.57 | 2024-2025 | Voquezna |
| Almatica Pharma LLC | $99.89 | 2022-2025 | Loreev Xr, Teriparatide, Gralise |
| Gilead Sciences, INC. | $89.49 | 2025 | |
| Eisai INC. | $73.36 | 2021 | |
| Sanofi Pasteur INC. | $59.87 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $57.20 | 2023-2024 | Edarbi, Edarbi, Edarbyclor |
| Xeris Pharmaceuticals, INC. | $54.40 | 2020-2021 | |
| Astellas Pharma US INC | $54.24 | 2025 | Veozah |
| Viatris Specialty LLC | $52.80 | 2025 | Yupelri |
| Currax Pharmaceuticals LLC | $48.30 | 2025 | Contrave |
| Mylan Specialty L.P. | $47.84 | 2024 | Yupelri |
| Janssen Biotech, INC. | $41.03 | 2019 | |
| Althera Pharmaceuticals LLC | $39.34 | 2021 | |
| Impel Pharmaceuticals INC. | $38.35 | 2023 | Trudhesa |
| Dexcom, INC. | $35.48 | 2021-2023 | Dexcom G6 Transmitter |
| Zyla Life Sciences, INC. | $32.50 | 2020 | |
| Aytu Biopharma, INC. | $32.43 | 2019 | |
| Hikma Pharmaceuticals USA | $28.40 | 2019 | |
| Intra-Sana Laboratories | $20.23 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Medicure Pharma INC. | $16.07 | 2024 | Zypitamag |
| Kaleo, INC. | $15.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.97 | 2023 | |
| Assertio Therapeutics, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Telegadis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.